A phase I safety trial of SPX 101 in healthy volunteers

Trial Profile

A phase I safety trial of SPX 101 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs SPX 101 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Jun 2017 According to a Spyryx Biosciences media release, an E-Poster of data from this trial presented at the European Cystic Fibrosis Society (ECFS) Conference 2017.
    • 20 Jun 2017 Results published in the Spyryx Biosciences Media Release
    • 24 May 2017 Results (n=32) presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top